The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Relationship of Lipoproteins to Cardiovascular Events
Open accessAbstract
Objectives This study sought to examine the relationship between niacin treatment, lipoproteins, and cardiovascular (CV) outcomes in this secondary analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial. Background During a 3-year follow-up in 3,414 patients with established CV disease and low high-density lipoprotein cholesterol (HDL-C) levels, combined niacin + low-density lipoprotein cholesterol (LDL-C)-lowering therapy did not reduce CV events compared with LDL-C-lowering therapy alone. Methods Subjects taking simvastatin and/or ezetimibe were randomized to receive extended-release (ER) niacin 1,500 to 2,000 mg or minimal immediate-release niacin (≤ 150 mg) as placebo at bedtime. LDL-C levels in both groups were maintained from 40 to 80 mg/dl. Hazard ratios were estimated by using Cox proportional hazards models for relationships between lipoproteins and the composite endpoint of CV death, myocardial infarction, acute coronary syndrome, ischemic stroke, or symptom-driven revascularization. Results CV outcomes were not associated with ER niacin in any baseline lipoprotein tertile. In a subset of patients in both the highest triglyceride (≥ 198 mg/dl) and lowest HDL-C (<33 mg/dl) tertiles, ER niacin showed a trend toward benefit (hazard ratio: 0.74, p = 0.073). In-trial LDL-C levels, non-HDL-C levels, and the total cholesterol/HDL-C ratio were positively associated with CV events in the control group, but these relationships were absent in the ER niacin group. Conclusions Baseline lipoprotein tertiles did not predict differential benefit or harm with ER niacin added to LDL-C-lowering therapy, but a small dyslipidemic subgroup may benefit. ER niacin attenuated expected relationships of lipoprotein risk factors with CV events, raising the possibility that nonlipoprotein actions of niacin could affect risk. (Niacin Plus Statin to Prevent Vascular Events [AIM-HIGH]; NCT00120289).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“subgroup analyses suggested possible benefits to TG lowering in patients with dyslipidemia.5, 6”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, randomized data from large outcome studies across broad populations regarding pharmacological TG lowering and effect on CV outcomes have been mixed (Table 4).1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finally, any benefits to TG‐lowering therapies may be most pronounced among statin‐treated patients in the higher range of TG elevation (ie, ≥200 mg/dL),4, 5, 6 for whom randomized prospectively designed outcome studies have not been previously conducted prior to the REDUCE‐IT study.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, TG reduction lowers several inflammatory markers associated with CV risk, and subgroup and post hoc analyses of outcome studies suggest possible reductions in major CV events with TG‐lowering therapy.3, 4, 5, 6, 7, 8, 9, 10, 11”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“The subgroup data (Table 5) from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid,6 Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM‐HIGH),5 and JELIS4 trials further support a prospective study of EPA in a broader patient population with hypertriglyceridemia, as exemplified in REDUCE‐IT, as a potent”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Clinical and epidemiological studies have demonstrated that triglyceride (TG) elevation is an independent risk factor for increased cardiovascular (CV) events”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Furthermore, TG reduction lowers several inflammatory markers associated with CV risk, and subgroup and post hoc analyses of outcome studies suggest possible reductions in major CV events with TG‐lowering therapy.3, 4, 5, 6, 7, 8, 9, 10, 11”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Epidemiological, biological, and genetic studies have provided robust evidence of a strong association between elevated TG levels and higher rates of CV events.1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [5]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
IX. On the problem of the most efficient tests of statistical hypotheses
Neyman, J., & Pearson, E. S. (1933) · Philosophical Transactions of the Royal Society of London Series A Containing Papers of a Mathematical or Physical Character · doi:10.1098/rsta.1933.0009 · Cited by 2,370
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Self-citationClofibrate and Niacin in Coronary Heart Disease
Stamler, J. (1975) · JAMA · doi:10.1001/jama.1975.03240160024021 · Cited by 1,750
ON THE PROBLEM OF THE MOST EFFICIENT TESTS OF STATISTICAL HYPOTHESES
Neyman, J., & Pearson, E. S. (1967) · University of California Press eBooks · doi:10.1525/9780520339897-008 · Cited by 1,545
Carlson, L. A., & Rosenhamer, G. (1988) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1988.tb15891.x · Cited by 685
HPS2-THRIVE Collaborative Group, Haynes, R., Jiang, L., Hopewell, J. C., Li, J., Chen, F., Parish, S., Landray, M. J., Collins, R., Armitage, J., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht055 · Cited by 676
Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness
Taylor, A. J., Villines, T. C., Stanek, E. J., Devine, P. J., Griffen, L., Miller, M. J., Weissman, N. J., & Turco, M. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907569 · Cited by 638
Nicotinic acid: the broad‐spectrum lipid drug. A 50th anniversary review
Carlson, L. A. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01528.x · Cited by 591
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–178 of 178
Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction
Zambon, A., Pirillo, A., Zambon, S., Norata, G. D., & Catapano, A. L. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00893-1 · Cited by 11
HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation
Παπαγεωργίου, Ν., Zacharia, E. M., Androulakis, E. S., Briasoulis, Α., Charakida, M., & Tousoulis, D. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1152264 · Cited by 12
Approach to the Patient With Moderate Hypertriglyceridemia
Subramanian, S. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac085 · Cited by 12
Dyslipidemia in Chronic Kidney Disease
Streja, E., & Streja, D. A. (2022) · Wiley eBooks · doi:10.1002/9781119105954.ch34 · Cited by 11
Elbadawi, N. S., Sobih, M. H., Soliman, M. Z., Mostafa, M. A., Kazibwe, R., & Soliman, E. Z. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164946 · Cited by 10
Cruz, D. E., Ahmed, H. M., Jones, S. R., Elshazly, M. B., & Martin, S. S. (2014) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-014-0382-9 · Cited by 10
Feingold, K. R. (2020) · Europe PMC (PubMed Central) · Cited by 10
Toth, P. P., Jones, S. R., Slee, A. E., Fleg, J. L., Marcovina, S. M., Lacy, M., McBride, R., & Boden, W. E. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.03.077 · Cited by 9
Self-citationHigh Density Lipoproteins: Is There a Comeback as a Therapeutic Target?
von Eckardstein, A. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_536 · Cited by 9
Mitchel, Y., Bays, H. E., Brinton, E. A., Triscari, J. M., Chen, E., Maccubbin, D., MacLean, A. A., Gibson, K., Ruck, R. A., Johnson‐Levonas, A. O., et al. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s70907 · Cited by 9
Lipid parameters in patients with acute coronary syndromes versus stable coronary artery disease
Vonbank, A., Saely, C. H., Rein, P., & Drexel, H. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12513 · Cited by 9
Pang, D., Nong, Z., Sutherland, B. G., Sawyez, C. G., Robson, D. L., Toma, J., Pickering, J. G., & Borradaile, N. M. (2016) · Pharmacology Research & Perspectives · doi:10.1002/prp2.233 · Cited by 9
Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort
Probstfield, J. L., Boden, W. E., Anderson, T. J., Branch, K. R., Kashyap, M. L., Fleg, J. L., Desvigne-Nickens, P. M., McBride, R., & McGovern, M. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.07.007 · Cited by 9
Self-citationMiller, M. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001136 · Cited by 7
Quispe, R., Al-Hijji, M. A., Swiger, K. J., Martin, S. S., Elshazly, M. B., Blaha, M. J., Joshi, P. H., Blumenthal, R. S., Sniderman, A. D., Toth, P. P., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.05.005 · Cited by 7
Hallén, J., & Sreeharan, N. (2018) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvy029 · Cited by 7
Combinatorial approaches for novel cardiovascular drug discovery: a review of the literature
Brogi, S., Tabanelli, R., & Calderone, V. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2104247 · Cited by 7
Stein, J. H. (2016) · Europe PMC (PubMed Central) · Cited by 7
Drexel, H., Lewis, B. S., Rosano, G. M. C., Saely, C. H., Tautermann, G., Huber, K., Dopheide, J. F., Kaski, J. C., MADER, A., Niessner, A., et al. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa126 · Cited by 7
Perspectives on a new prescription omega-3 fatty acid, icosapent ethyl, for hypertriglyceridemia
Jacobson, T. A. (2014) · Clinical Lipidology · doi:10.2217/clp.14.10 · Cited by 6
Critical review of non-statin treatments for dyslipoproteinemia
Pang, J., Chan, D. C., & Watts, G. F. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.888312 · Cited by 6
Current Controversies With Recent Cholesterol Treatment Guidelines
Phillips, E., & Saseen, J. J. (2015) · Journal of Pharmacy Practice · doi:10.1177/0897190015615880 · Cited by 6
An Uninformative Truth: The Logic of Amarin’s Off-Label Promotion
Hey, S. P., & Kesselheim, A. S. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1001978 · Cited by 6
Masuda, Y., Kurikawa, N., & Nishizawa, T. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.041 · Cited by 6
Leatherman, S. M., Ferguson, R. E., Hau, C., Harrington, K. M., Granowitz, C. B., Philip, S., Toth, P. P., Bhatt, D. L., & Boden, W. E. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.982815 · Cited by 6
Self-citationKaye, A. D., COFFMAN, G. D., Mashaw, S. A., Thomassen, A. S., Broocks, K. M., Anwar, A. I., Ahmadzadeh, S., & Shekoohi, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47060400 · Cited by 5
Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels
Colantonio, L. D., & Bittner, V. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.09.011 · Cited by 5
The Role of Niacin in the Management of Dyslipidemia
Keenan, J. M. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.81725 · Cited by 5
Achieving optimal lipid goals in the metabolic syndrome: A global health problem
Karalis, D. G. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.07.039 · Cited by 4
Heterogeneity of diabetic dyslipidemia, data from the NHANES (2011–2016)
Li, Y.-S., Liu, J., Huang, N., Cui, H., & Li, J. (2024) · Medicine · doi:10.1097/md.0000000000037173 · Cited by 4
Role of omega-3 polyunsaturated fatty acids in cardiovascular risk management
Podzolkov, V. I., & Владимирович, П. М. (2020) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2020-2589 · Cited by 4
Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease of Patients with Diabetes
Feingold, K. R. (2020) · Europe PMC (PubMed Central) · Cited by 4
Refocusing the AIM on HDL in the metabolic syndrome
McGarrah, R. W. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.06.051 · Cited by 4
Nelson, J. R. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000130 · Cited by 3
Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels
Colantonio, L. D., & Bittner, V. (2015) · Cardiology Clinics · doi:10.1016/j.ccl.2015.01.004 · Cited by 3
Narang, A., Mor‐Avi, V., Bhave, N. M., Tarroni, G., Corsi, C., Davidson, M. H., Lang, R. M., & Patel, A. R. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.12.006 · Cited by 3
Lyubarova, R., Albers, J. J., Marcovina, S. M., Yao, Y., McBride, R., Topliceanu, A., Anderson, T. J., Fleg, J. L., Desvigne-Nickens, P. M., Kashyap, M. L., et al. (2019) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248419852955 · Cited by 3
Self-citationBrinton, E. A., Triscari, J. M., Brudi, P., Chen, E., Johnson‐Levonas, A. O., Sisk, C. M., Ruck, R. A., MacLean, A. A., Maccubbin, D., & Mitchel, Y. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0282-8 · Cited by 3
Combination Therapy for Dyslipidemia
Davidson, D., Wilkinson, M. J., & Davidson, M. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00027-x · Cited by 3
Niacin: Risk Benefits and Role in Treating Dyslipidemias
Guyton, J. R., Campbell, K. B., & Lakey, W. C. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_26 · Cited by 3
Self-citationRodríguez, Á. D., Cumplido, A. S., Núñez-Cortés, J. M., de Miguel, M. R., & Peña, M. L. O. (2017) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2017.07.004 · Cited by 3
Optimizing nicotinic acid delivery for durable antilipolysis and improved metabolic control
Kroon, T. (2016) · Epsilon Open Archive (Sveriges lantbruksuniversitet biblioteket (Swedish University of Agricultural Sciences)) · Cited by 3
Heuristics and Explanation in Translational Medicine
Hey, S. P. (2019) · Perspectives in biology and medicine · doi:10.1353/pbm.2019.0039 · Cited by 2
Luca, L. D., Temporelli, P. L., Gulizia, M. M., Gonzini, L., Ammaturo, T., Tedesco, L., Pede, S., Oliva, F. G., Gabrielli, D., Colivicchi, F., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.07.036 · Cited by 2
Highlights of the Year in JACC 2013
DeMaria, A. N., ADLER, E. D., Bax, J. J., Ben‐Yehuda, O., Feld, G. K., Greenberg, B., Hall, J. L., Hlatky, M. A., Lew, W. Y. W., Lima, J. A. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.002 · Cited by 2
Advances in the management of dyslipidemia
Kampangkaew, J., Pickett, S., & Nambi, V. (2017) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000415 · Cited by 2
Matsuoka, Y., Ike, A., Ogawa, M., Gondo, K., Shirai, K., Sugihara, M., Nose, D., Nishikawa, H., Iwata, A., Kawamura, A., et al. (2017) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.09.011 · Cited by 2
Kimura, M., Takeda, T., Tsujino, Y., Matsumoto, Y., Yamaji, M., Sakaguchi, T., Maeda, K., Mabuchi, H., & Murakami, T. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64010 · Cited by 2
Genetic Disorders of HDL Metabolism
Lilley, J. S., Linton, M. F., & Fazio, S. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_12 · Cited by 2
Rodríguez, Á. D., Cumplido, A. S., Núñez-Cortés, J. M., de Miguel, M. R., & Peña, M. L. O. (2017) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2017.04.003 · Cited by 2
Management of Hyperlipidemia in 2015
Feingold, K. R. (2015) · The Endocrine Society eBooks · doi:10.1210/mtp4.9781936704941.ch24 · Cited by 2
Lipoprotein(a) in Cardiovascular Disease: What Clinicians Need to Know: A Narrative Review
Ricottini, E., Ciavaroli, N. G., Cristo, A. D., Lentini, A. E., Trunfio, T. A., D’Antonio, L., Mangiacapra, F., Nusca, A., Cammalleri, V., Melfi, R., et al. (2026) · Therapeutics · doi:10.3390/therapeutics3020011 · Cited by 1
Combination Therapy with Statins
Singh, A., & Davidson, M. H. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.08.005 · Cited by 1
The Role of Omega-3 Fatty Acids in Dyslipidemias
Brandt, E. J., & Davidson, M. H. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_5 · Cited by 1
Lipids in Coronary Heart Disease
Martin, S. S., Joshi, P. H., & Michos, E. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802385-3.00007-3 · Cited by 2
COPPLE, T. M., & Ciffone, N. A. (2017) · The Nurse Practitioner · doi:10.1097/01.npr.0000526627.04268.80 · Cited by 1
The Role of Niacin in the Management of Dyslipidemia†
Keenan, J. M. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.04.052 · Cited by 1
Guyton, J. R., McGovern, M. E., & Carlson, L. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00024-4 · Cited by 1
Self-citationReyes‐Soffer, G., & Ginsberg, H. N. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00035-9 · Cited by 1
Lipid and lipoprotein metabolism, hypolipidemic agents, and therapeutic goals
Reyes‐Soffer, G., & Ginsberg, H. N. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch17
Hyperlipidemia: Where Is the Evidence for Combination Therapy?
Tannock, L. R. (2015) · The Endocrine Society eBooks · doi:10.1210/mtp4.9781936704941.ch26
Hypertriglyceridemia: Should We Treat?
Brinton, E. A. (2014) · The Endocrine Society eBooks · doi:10.1210/mtp3.9781936704835.ch27
Icosapent ethyl in hypertriglyceridaemia: a guide to its use
Lyseng-Williamson, K. A., McCormack, P. L., & Kim, E. (2016) · Drugs & Therapy Perspectives · doi:10.1007/s40267-016-0278-5
Elevated Triglycerides, Atherosclerosis and Adverse Clinical Events
Jones, S. R., & Nakhla, S. (2015) · Springer eBooks · doi:10.1007/978-3-319-20415-4_5
Disadvantages of Current LDL-cholesterol Lowering and the Role of PCSK9 Inhibitors.
Roncevic, S. M., Gobić, D., Jurjević, T. Z., Miculinić, Ž. R., & Zaputović, L. (2016) · Cardiologia Croatica · doi:10.15836/ccar.2016.330
Triglycerides: Mendelian Randomization Studies Suggest Causal Role, but How to Treat in 2019?
Park, J. E., & Miller, M. J. (2019) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-019-0603-3
Drugs for Treatment of Dyslipidemia Available in the USA
Streja, E., & Streja, D. A. (2019) · Springer eBooks · doi:10.1007/978-3-319-97765-2_13
Peters, K. M. (2019) · Scholarship@Western (Western University)
Quispe, R., Das, T. M., & Michos, E. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-75055-8_2
Schaefer, E. J. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000082
Toth, P. P. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2023.01.007
Long Way of Evaluating Niacin for Atherosclerosis Treatment
Poznyak, A. V., Khotina, V. A., Pleshko, E. M., Sukhorukov, V. N., Glanz, V. Y., & Orekhov, A. N. (2024) · OnLine Journal of Biological Sciences · doi:10.3844/ojbsci.2024.349.357
Estudios de prevención cardiovascular en población con hipertrigliceridemia
Muñiz-Grijalvo, O. (2025) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2025.500819
Cardiovascular prevention studies in a population with hypertriglyceridemia
Muñiz-Grijalvo, O. (2025) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.500819
Clerc, A., Puricel, S., Faucherre, Y., Magnin, J., Lehmann, S., Garín, D., Ferry, C., Meier, P., Togni, M., & Cook, S. (2025) · Journal of Interventional Cardiology · doi:10.1155/joic/5030966
Arıkan, Y. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.124018
Multitargets drug design for screening of phytochemicals to cure metabolic disorders
Ogunlakin, A. D., Edema, A. A., Elbasyouni, A., Adegoke, A. A., Akinwumi, I. A., Oyebamiji, A. K., Ojo, O. A., Adebodun, G. O., Akinmurele, O. J., Oladejo, O. A., et al. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-31698-2.00020-5 · Cited by 4
Metadata
- Authors
- Guyton, J. R., Slee, A. E., Anderson, T., Fleg, J. L., Goldberg, R. B., Kashyap, M. L., Marcovina, S. M., Nash, S. D., O'Brien, K. D., Weintraub, W. S., Xu, P., Zhao, X.-Q., & Boden, W. E.
- Affiliations
- Duke University (US)
- University of Calgary (CA)
- National Heart, Lung, and Blood Institute (US)
- University of Miami (US)
- University of California, Irvine (US)
- University of Washington (US)
- SUNY Upstate Medical University (US)
- Albany Stratton VA Medical Center Albany (US)
- Corresponding author
- Guyton, John R.
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 62
- Issue
- 17
- Pages
- 1580-1584
- ISSN
- 0735-1097 (ISSN-L)
- PMC
- PMC3862446
- OpenAlex
- W2189339462
- Cited by
- 182
- References
- 23
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 10 · 2023: 6 · 2022: 6 · 2021: 5 · 2020: 15 · 2019: 16 · 2018: 12 · 2017: 15 · 2016: 28 · 2015: 33 · 2014: 22 · 2013: 3
- FWCI
- 26.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (U01-HL-081616, U01-HL-081649)
- Abbott Laboratories
- Merck & Co.
- Regeneron
- Sanofi US
- Genzyme Corporation, Isis Pharmaceuticals
- Amgen
- Amarin
- GlaxoSmithKline
- Merck
- Roche
- Abbott
- AstraZeneca
- Eli Lilly
- Sanofi
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- nicotinic acid, lipoproteins, cardiovascular events, AIM-HIGH trial, extended-release niacin, low HDL cholesterol, triglycerides, LDL-C lowering therapy, simvastatin, ezetimibe, non-HDL cholesterol, TC/HDL-C ratio, cardiovascular risk prediction
- MeSH terms
- Aged, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Lipoproteins, Cholesterol, HDL, Male, Middle Aged, Niacin, Prospective Studies, Triglycerides, Global Health, Biomarkers, Treatment Outcome, Metabolic Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
